Novartis AG Common Stock (NY:NVS)

140.35 -0.65 (-0.46%)

Delayed Quote Updated: 9:40 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

59 60 Next >

PU Prime Broadens Portfolio with New Global Indices

June 11, 2025

Via GlobePRwire

Topics Derivatives Economy

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

June 11, 2025

EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Is Novartis Gaining or Losing Market Support? ↗

June 04, 2025

Via Benzinga

Earnings Scheduled For April 29, 2025 ↗

April 29, 2025

Via Benzinga

Earnings Preview For Novartis ↗

April 28, 2025

Via Benzinga

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

June 11, 2025

From FN Media Group LLC

Via GlobeNewswire

2 Dividend Growth Stocks to Buy and Hold Forever ↗

June 06, 2025

Via The Motley Fool

Topics Intellectual Property

Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position ↗

June 05, 2025

Clear Street’s initiated with a $3 price target, highlighting RPT904b as a “potentially best-in-class anti-IgE antibody.”

Via Stocktwits

Topics ETFs

Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 ↗

May 29, 2025

FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

May 28, 2025

Via Benzinga

The Smartest Vanguard ETF to Buy With $500 Right Now ↗

May 21, 2025

Via The Motley Fool

Topics ETFs

Prediction: This "Magnificent Seven" Stock Will Be the Most Valuable Company in the World in 10 Years ↗

May 16, 2025

This company stands to benefit from the advances in artificial intelligence more than any other business.

Via The Motley Fool

Topics Artificial Intelligence

Lazard Transforms Mutual Fund Into IEQ ETF Amid Rising Demand For International Stocks ↗

May 15, 2025

IEQ inherits the portfolio DNA of its mutual fund ancestor, now in the tax-efficient wrapper increasingly favored by investors.

Via Benzinga

Topics ETFs

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 ↗

May 14, 2025

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

Via Benzinga

Here's My Favorite High-Dividend ETF to Buy Right Now ↗

May 14, 2025

Via The Motley Fool

Topics ETFs

Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say ↗

May 12, 2025

JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting...

Via Stocktwits

Topics ETFs Government Stocks

S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform ↗

May 12, 2025

It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.

Via Investor's Business Daily

Topics Government Stocks

Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study ↗

May 09, 2025

Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.

Via Benzinga

FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight ↗

May 06, 2025

FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.

Via Benzinga

BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion ↗

May 05, 2025

BioNTech's Q1 revenue hit $192 million, beating estimates; company confirms 2025 outlook and names new CFO ahead of oncology-focused expansion.

Via Benzinga

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead ↗

May 01, 2025

Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a...

Via Stocktwits

Topics Stocks

Humana Does Not Alter 2025 Outlook Despite Sales Miss And Medicare Membership Decline ↗

April 30, 2025

Humana beat Q1 EPS estimates with $11.58, reaffirmed 2025 guidance, and outlined margin goals despite a drop in Medicare Advantage membership.

Via Benzinga

Topics Earnings

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million ↗

April 30, 2025

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to close in H2 2025.

Via Benzinga

AppLovin Stock Tumbles After Edgewater Research Cuts Estimates Citing Rising Competition ↗

April 30, 2025

Edgewater noted that the mobile gaming macro environment appears to be decelerating gradually, while competition from both Meta and Alphabet is intensifying.

Via Stocktwits

Topics Artificial Intelligence

Regulus Therapeutics Stock Skyrockets On $1.7B Acquisition Offer From Novartis ↗

April 30, 2025

According to the terms of the deal, Novartis, through a subsidiary, will initiate a tender offer to acquire all of Regulus' outstanding shares for an initial price of $7.00 per share or $800 million.

Via Stocktwits

Novartis Q1 Earnings Beat Street View, CEO 'Confident' In Delivering Upgraded Guidance ↗

April 29, 2025

Novartis raises 2025 sales and profit forecast as key drugs drive strong Q1 results; core operating income up 23% to $5.6 billion on higher net sales.

Via Benzinga

Topics Earnings

Novartis Creeps Toward A Breakout On Its Beat-And-Raise ↗

April 29, 2025

Shares are consolidating and are now trading above their 50-day and 200-day lines.

Via Investor's Business Daily

US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week ↗

April 29, 2025

U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this...

Via Benzinga

General Motors, Coca-Cola And 3 Stocks To Watch Heading Into Tuesday ↗

April 29, 2025

Via Benzinga

Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report ↗

April 28, 2025

Saynor told Reuters that the proposal, put forth by Novartis and Sanofi in a letter to the Financial Times on Wednesday, overlooks the structural drivers of high drug prices in the United States and...

Via Stocktwits

Topics Government Intellectual Property Lawsuit

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.